Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
Status:
Completed
Trial end date:
2020-03-27
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the efficacy and safety of the combination therapy
with enzalutamide + androgen deprivation therapy (ADT) and the combination therapy with
flutamide + ADT in patients with castration resistant prostate cancer who had relapsed during
combined androgen blockade (CAB) therapy with bicalutamide and ADT. This study also
investigated the order of alternative antiandrogen therapy (AAT) by changing the 1st line
medication after relapse of prostate-specific antigen (PSA).